Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.

Poukka M, Lund-Aho T, Raittinen P, Nikkilä A, Kivinen K, Lundán T, Porkka K, Lohi O.

J Pediatr Hematol Oncol. 2018 Jul 24. doi: 10.1097/MPH.0000000000001267. [Epub ahead of print]

PMID:
30045148
2.

Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.

Kivioja JL, Lopez Martí JM, Kumar A, Kontro M, Edgren H, Parsons A, Lundán T, Wolf M, Porkka K, Heckman CA.

Leuk Lymphoma. 2018 Mar;59(3):725-732. doi: 10.1080/10428194.2017.1357174. Epub 2017 Aug 4.

PMID:
28776436
3.

A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.

Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM, Kakko S, Putkonen M, Ollikainen H, Terävä V, Kutila A, Launonen K, Räsänen A, Sikiö A, Suominen M, Bazia P, Kananen K, Selander T, Kuittinen T, Remes K, Jantunen E.

Bone Marrow Transplant. 2016 Mar;51(3):372-6. doi: 10.1038/bmt.2015.236. Epub 2015 Oct 5.

4.

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma.

Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Huotari V, Mäntymaa P, Siitonen S, Uotila L, Penttilä TL, Juvonen V, Selander T, Remes K.

Blood Cancer J. 2014 Oct 10;4:e250. doi: 10.1038/bcj.2014.69.

5.

The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.

Rajala HL, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, Hamm DE, Zaman SA, Lopez Marti JM, Andersson EI, Jerez A, Porkka K, Maciejewski JP, Loughran TP, Mustjoki S.

Haematologica. 2015 Jan;100(1):91-9. doi: 10.3324/haematol.2014.113142. Epub 2014 Oct 3.

6.

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.

Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA.

Leukemia. 2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27. No abstract available.

PMID:
24573384
7.

Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, Vapaatalo M, Remes K, Lundán T, Hjorth-Hansen H, Vakkila J, Simonsson B, Mustjoki S, Porkka K.

Eur J Haematol. 2014;92(5):413-20. doi: 10.1111/ejh.12258. Epub 2014 Jan 28.

PMID:
24372965
8.

Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K.

Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20.

9.

Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.

Silvennoinen R, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, Säily M, Sikiö A, Opas J, Penttilä K, Kuittinen T, Honkanen T, Lundán T, Juvonen V, Luukkaala T, Remes K.

Br J Haematol. 2013 Feb;160(4):561-4. doi: 10.1111/bjh.12139. Epub 2012 Dec 4. No abstract available.

PMID:
23206270
10.

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

Gruber FX, Lundán T, Goll R, Silye A, Mikkola I, Rekvig OP, Knuutila S, Remes K, Gedde-Dahl T, Porkka K, Hjorth-Hansen H.

Med Oncol. 2012 Mar;29(1):219-26. doi: 10.1007/s12032-010-9781-z. Epub 2011 Jan 8.

PMID:
21221851
11.

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.

Olsson-Strömberg U, Hermansson M, Lundán T, Ohm AC, Engdahl I, Höglund M, Simonsson B, Porkka K, Barbany G.

Eur J Haematol. 2010 Nov;85(5):399-404. doi: 10.1111/j.1600-0609.2010.01506.x.

PMID:
20659155
12.

A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).

Mustjoki S, Hernesniemi S, Rauhala A, Kähkönen M, Almqvist A, Lundán T, Porkka K.

Haematologica. 2009 Oct;94(10):1469-71. doi: 10.3324/haematol.2009.008094. No abstract available.

13.

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.

Mustjoki S, Rohon P, Rapakko K, Jalkanen S, Koskenvesa P, Lundán T, Porkka K.

Leukemia. 2010 Jan;24(1):219-22. doi: 10.1038/leu.2009.190. Epub 2009 Sep 24. No abstract available.

PMID:
19776759
14.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R, Wild R, Luo R, Arnan M, Brethon B, Eccersley L, Hjorth-Hansen H, Höglund M, Klamova H, Knutsen H, Parikh S, Raffoux E, Gruber F, Brito-Babapulle F, Dombret H, Duarte RF, Elonen E, Paquette R, Zwaan CM, Lee FY.

Blood. 2008 Aug 15;112(4):1005-12. doi: 10.1182/blood-2008-02-140665. Epub 2008 May 13.

15.

Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.

Lundán T, Juvonen V, Mueller MC, Mustjoki S, Lakkala T, Kairisto V, Hochhaus A, Knuutila S, Porkka K.

Haematologica. 2008 Feb;93(2):178-85. doi: 10.3324/haematol.11910. Epub 2008 Jan 26.

16.

Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia.

Mustjoki S, Lundán T, Knuutila S, Porkka K.

Leukemia. 2007 Nov;21(11):2363-8. Epub 2007 Jun 14. No abstract available.

PMID:
17568811
17.

RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability.

Heikkinen K, Rapakko K, Karppinen SM, Erkko H, Knuutila S, Lundán T, Mannermaa A, Børresen-Dale AL, Borg A, Barkardottir RB, Petrini J, Winqvist R.

Carcinogenesis. 2006 Aug;27(8):1593-9. Epub 2006 Feb 12.

18.

Childhood-onset osteoarthritis, tall stature, and sensorineural hearing loss associated with Arg75-Cys mutation in procollagen type II gene (COL2A1).

Löppönen T, Körkkö J, Lundan T, Seppänen U, Ignatius J, Kääriäinen H.

Arthritis Rheum. 2004 Dec 15;51(6):925-32. Review.

19.

Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9.

Lundán T, Volin L, Ruutu T, Knuutila S, Porkka K.

Leukemia. 2005 Jan;19(1):138-40. No abstract available.

PMID:
15510201
20.

Characterization and expression of the human WNT4; lack of associated germline mutations in high--to moderate--risk breast and ovarian cancer.

Peltoketo H, Allinen M, Vuosku J, Kujala S, Lundan T, Salminen A, Winqvist R, Vainio S.

Cancer Lett. 2004 Sep 15;213(1):83-90.

PMID:
15312687

Supplemental Content

Loading ...
Support Center